Lyell Immunopharma, Inc.
Price Action
Technical Summary
CONSOLIDATINGLyell Immunopharma, Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is moderate (RS Rating: 65), indicating performance broadly in line with the market. Earnings contraction of 5% provides fundamental context to the price action. Investors should exercise caution due to high volatility (108% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $22.46 | -10.69% | BELOW |
| 50 SMA | $22.13 | -9.34% | BELOW |
| 100 SMA | $24.51 | -18.17% | BELOW |
| 150 SMA | $22.82 | -12.10% | BELOW |
| 200 SMA | $20.14 | -0.38% | BELOW |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is LYEL in an uptrend right now?
LYEL has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is LYEL overbought or oversold?
LYEL's RSI (14) is 44. The stock is in neutral territory, neither overbought nor oversold.
Is LYEL outperforming the market?
LYEL has a Relative Strength (RS) Rating of 65 out of 99. LYEL is performing about average compared to the market.
Where is LYEL in its 52-week range?
LYEL is trading at $20.06, which is 45% of its 52-week high ($45.00) and 33% above its 52-week low ($7.65).
How volatile is LYEL?
LYEL has a Beta of 1.87 and 52-week volatility of 108%. It's more volatile than the S&P 500 - expect bigger swings.